Tissue Factor (F3) Human siRNA Oligo Duplex (Locus ID 2152)

CAT#: SR301499

F3 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each

Specifications

Product Data

• Purity: HPLC purified
• Quality Control: Tested by ESI-MS
• Sequences: Available with shipment
• Components: F3 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 2152)
  Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
  Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
• Stability: One year from date of shipment when stored at -20°C.
• Number of Transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
• Note: Single siRNA duplex (10nmol) can be ordered.

Reference Data

• RefSeq: NM_001178096, NM_001993
• UniProt ID: P13726
• Synonyms: CD142; TF; TFA
• Summary: This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces, for example, on monocytes. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. Platelets and monocytes have been shown to express this coagulation factor under procoagulatory and proinflammatory stimuli, and a major role in HIV-associated coagulopathy has been described. Platelet-dependent monocyte expression of coagulation factor III has been described to be associated with Coronavirus Disease 2019 (COVID-19) severity and mortality. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Aug 2020]
• Performance Guaranteed: OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
  
  For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).